Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Eltrekibart · 2 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| Eltrekibart + Placebo | EXPERIMENTAL | Participants will receive eltrekibart with placebo, eltrekibart or mirikizumab. |
| Mirikizumab + Placebo | EXPERIMENTAL | Participants will receive mirikizumab and placebo or mirikizumab. |
| Eltrekibart + Mirikizumab | EXPERIMENTAL | Participants will receive eltrekibart and mirikizumab in combination or separately as monotherapy. |
| Placebo | EXPERIMENTAL | Participants will receive placebo or mirikizumab. |
| Eltrekibart Dose 1 | EXPERIMENTAL | Eltrekibart will be given subcutaneously (SC). |
| Eltrekibart Dose 2 | EXPERIMENTAL | Eltrekibart will be given SC. |
| Eltrekibart Dose 3 | EXPERIMENTAL | Eltrekibart will be given SC. |
| Name | Type | Description |
|---|---|---|
| Eltrekibart | DRUG | Administered |
| Mirikizumab | DRUG | Administered |
| Placebo | DRUG | Administered |
Inclusion Criteria: * Have had an established diagnosis of UC of ≥3 months in duration before baseline. * Have moderately to severely active UC as assessed by the UC disease activity score. * Have an inadequate response to, loss of response to, or intolerance to at least one conventional medication...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 5 | PHASE3 | Lutikizumab |
| Incyte Corporation | INCY | 6 | PHASE3 | Povorcitinib |
| Novartis AG Sponsored ADR | NVS | 12 | PHASE3 | secukinumab |
| MoonLake Immunotherapeutics Class A | MLTX | 2 | PHASE3 | Sonelokimab |
| Sanofi SA Sponsored ADR | SNY | 2 | PHASE2 | Brivekimig |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Eltrekibart |
| Pfizer Inc. | PFE | 1 | PHASE2 | Ritlecitinib |
| Merck & Co., Inc. | MRK | 1 | PHASE2 | Tulisokibart |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Zasocitinib |
| Zura Bio Limited Class A | ZURA | 1 | PHASE2 | Tibulizumab Dose A, Tibulizumab Dose B |
| Sonoma Pharmaceuticals, Inc. | SNOA | 2 | PHASE1 | SBT777101 |
| Evommune, Inc. | EVMN | 1 | EARLY_PHASE1 | EVO101 |